Skip to main content
. 2016 Sep 14;11(9):e0162594. doi: 10.1371/journal.pone.0162594

Fig 3. ARQ 087 inhibits the FGFR pathway in cancer cell lines.

Fig 3

(A) NCI-H716, SNU-16, and KATO-III cells were treated with the indicated concentrations of ARQ 087 for 2 hours, and phospho-FGFR was assessed by Western blot analyses. β-Actin was used as a loading control. (B) NCI-H716 and SNU-16 cells were treated with increasing concentrations of ARQ 087 from 0 μM to 3 μM for 2 hours. The quantity of indicated protein was assessed by Western blot analyses. β-Actin was used as a loading control. (C) KG-1 cells were treated with indicated concentrations of ARQ 087 for 2 hours followed by stimulation with a mixture of FGF1/FGF2/FGF7 for 15 minutes. Cell lysates were analyzed by Western blot to determine the expression of phospho-FGFR, phospho-ERK, and β-actin.